Skip to main content

Table 3 Cumulative, index admission and 3-month follow-up odds ratios

From: The use of enoxaparin as bridge to therapeutic INR after LVAD implantation

Outcomes Unadjusted OR (CI) P Adjusted OR (CI)a P
Cumulative
 Bleeding events 1.12 (0.6–2.2) 0.73 1.2 (0.5–2.8) 0.62
 CVA 0.39 (0.1–1.8) 0.22 0.42 (0.1–2.6) 0.35
Index
 Bleeding events 1.01 (0.4–2.8) 0.99 0.91 (0.3–3.0) 0.88
 CVA 0.42 (0.6–3.4) 0.42 0.67 (0.1–6.4) 0.73
Follow-up
 Bleeding events 0.67 (0.3–1.6) 0.37 0.85 (0.3–2.3) 0.76
 CVA n/a n/a n/a n/a
  1. aAdjusted for age, sex, race, type of LVAD, INTERMACS classification, type of cardiomyopathy, coronary artery disease prior stroke, chronic kidney disease, atrial fibrillation, hypertension, diabetes mellitus, obesity and obstructive sleep apnea
  2. CI Confidence Interval, CVA Cerebrovascular Accident, OR Odds Ratio